Nargiz Majidova

Maltepe, 34846, Turkey

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 62 publications

Erythrocyte Transfusion as an Independent Predictor of Survival but Not Immune-Related Toxicity in Nivolumab-Treated Metastatic NSCLC: A Multicenter Cohort.

Erythrocyte Transfusion as an Independent Predictor of Survival but Not Immune-Related Toxicity in Nivolumab-Treated Metastatic NSCLC: A Multicenter Cohort.

Journal: Medicina (Kaunas, Lithuania)
Published: July 09, 2026

Impact of adjuvant endocrine therapy on disease-free survival in early triple-positive breast cancer: a multicenter retrospective cohort study of the Turkish oncology group.

Impact of adjuvant endocrine therapy on disease-free survival in early triple-positive breast cancer: a multicenter retrospective cohort study of the Turkish oncology group.

Journal: BMC cancer
Published: June 04, 2026

Long-Term Outcomes and Conditional Recurrence-Free Survival in Stage II Colon Cancer: The Impact of Surveillance and Recurrence Detection Strategies.

Long-Term Outcomes and Conditional Recurrence-Free Survival in Stage II Colon Cancer: The Impact of Surveillance and Recurrence Detection Strategies.

Journal: Journal of clinical medicine
Published: May 17, 2026

Real-World Outcomes of CDK4/6 Inhibitors in Germline BRCA1/2-Mutated Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study.

Real-World Outcomes of CDK4/6 Inhibitors in Germline BRCA1/2-Mutated Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study.

Journal: Current oncology (Toronto, Ont.)
Published: May 02, 2026

Immune-related adverse events as predictors of pathological complete response in early-stage triple-negative breast cancer treated with pembrolizumab.

Immune-related adverse events as predictors of pathological complete response in early-stage triple-negative breast cancer treated with pembrolizumab.

Journal: Immunotherapy
Published: April 21, 2026

First-Line Treatment After Perioperative FLOT in Recurrent Gastric and Gastroesophageal Junction Cancer: A Turkish Oncology Group (TOG) Multicenter Real-World Analysis.

First-Line Treatment After Perioperative FLOT in Recurrent Gastric and Gastroesophageal Junction Cancer: A Turkish Oncology Group (TOG) Multicenter Real-World Analysis.

Journal: Medicina (Kaunas, Lithuania)
Published: April 15, 2026

Correction: Efficacy of gemcitabine plus nab-paclitaxel in second-line treatment of metastatic pancreatic cancer.

Correction: Efficacy of gemcitabine plus nab-paclitaxel in second-line treatment of metastatic pancreatic cancer.

Journal: Scientific reports
Published: April 03, 2026

Comparison of flat-dose versus weight-based dose nivolumab treatment in NSCLC patients.

Comparison of flat-dose versus weight-based dose nivolumab treatment in NSCLC patients.

Journal: Scientific reports
Published: February 20, 2026

Baseline vitamin D status and clinical outcomes in advanced non-small cell lung cancer patients treated with nivolumab.

Baseline vitamin D status and clinical outcomes in advanced non-small cell lung cancer patients treated with nivolumab.

Journal: Scientific reports
Published: February 01, 2026

Antibody-drug conjugate sequencing in HER2-positive metastatic breast cancer: Real-world outcomes of trastuzumab deruxtecan with and without prior T-DM1 exposure.

Antibody-drug conjugate sequencing in HER2-positive metastatic breast cancer: Real-world outcomes of trastuzumab deruxtecan with and without prior T-DM1 exposure.

Journal: Breast (Edinburgh, Scotland)
Published: January 21, 2026

Antibody-drug conjugate sequencing in HER2-positive metastatic breast cancer: Real-world outcomes of trastuzumab deruxtecan with and without prior T-DM1 exposure.

Antibody-drug conjugate sequencing in HER2-positive metastatic breast cancer: Real-world outcomes of trastuzumab deruxtecan with and without prior T-DM1 exposure.

Journal: Breast (Edinburgh, Scotland)
Published: January 21, 2026

Efficacy, Safety, and Survival Outcomes of Immune Checkpoint Inhibitors in Patients with Mismatch Repair-Deficient Colorectal Cancer: A Retrospective, Multicenter Study.

Efficacy, Safety, and Survival Outcomes of Immune Checkpoint Inhibitors in Patients with Mismatch Repair-Deficient Colorectal Cancer: A Retrospective, Multicenter Study.

Journal: Journal of clinical medicine
Published: January 17, 2026
Showing 1-12 of 62

Last Updated: 09/26/2026